AstraZeneca could sell, spin off $15B worth of assets

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca (AZN) is reviewing its neuroscience and anti-infection businesses and hopes to announce news "in the near future," CEO Pascale Soriot says following the company's Q1 earnings.

Astra could sell or spin off the operations - which analysts reckon could bring in $15B but which the company views as non-core - or bring in partners.

AstraZeneca is exploring options similar to Novartis' and GlaxoSmithKline's multibillion-dollar asset swap.

However, Soriot declined to comment on a report that Pfizer (PFE) had offered over $100B to buy AstraZeneca.

Shares are +5% premarket.